BIOMAT Database Logo BIOMAT Database Logo

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. 1994

A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Biocine R & D Vaccines, Siena, Italy.

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129G, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-linked immunosorbent assay titers to pertussis toxin, filamentous hemagglutinin, and pertactin, as well as the pertussis toxin-neutralizing titer measured by the Chinese hamster ovary cell assay, were significantly higher after the acellular vaccine was given. Both vaccines induced adequate levels of anti-diphtheria and anti-tetanus antibodies. We conclude that the recombinant acellular pertussis vaccine produces fewer reactions than the whole-cell vaccine and provides a high antibody response against the antigens of Bordetella pertussis involved in bacterial adhesion and systemic toxic effects.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010567 Pertussis Vaccine A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed) Vaccine, Pertussis
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001886 Bordetella pertussis A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath. Bacterium tussis-convulsivae,Haemophilus pertussis,Hemophilus pertussis
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
August 1995, The Journal of pediatrics,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation.
March 1985, Vaccine,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants.
December 2003, The Southeast Asian journal of tropical medicine and public health,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
January 1994, Pediatrics,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.
May 1996, Archives of pediatrics & adolescent medicine,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group.
August 1991, The Journal of pediatrics,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Priming with whole-cell versus acellular pertussis vaccine.
February 2013, The New England journal of medicine,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
September 1998, Pediatrics,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy.
January 2022, Medical principles and practice : international journal of the Kuwait University, Health Science Centre,
A Podda, and E C De Luca, and B Contu, and R Furlan, and A Maida, and A Moiraghi, and D Stramare, and L Titone, and F Uxa, and F Di Pisa, and S Peppoloni
Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
March 2002, European journal of pediatrics,
Copied contents to your clipboard!